Chemotherapy Induced Nausea Vomiting Market Report and Forecast 2025-2034

The chemotherapy induced nausea vomiting market was valued at USD 1.72 Billion in 2024 driven by innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 4.50% during the forecast period of 2025-2034 and attain a market value of USD 2.67 Billion by 2034. The rising cancer incidence is boosting the need for effective antiemetics, supporting long-term market expansion. Advancements in R&D and personalized medicine are driving innovation in targeted and combination chemotherapy induced nausea and vomiting treatments.

Chemotherapy Induced Nausea Vomiting Market Overview

Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of cancer treatment, caused by the body’s reaction to chemotherapy drugs. It can occur during or after treatment and may be acute, delayed, or anticipatory. CINV significantly affects patients' quality of life and treatment adherence, making the use of antiemetic medications essential for effective symptom management and patient comfort. The market is expected to grow at a CAGR of 4.50% during the forecast period of 2025-2034.

Chemotherapy Induced Nausea Vomiting Market Growth Drivers

Adoption of Ready-to-use Injectables to Drive Market Growth

Growing demand for convenient, safe, and efficient antiemetic delivery, along with a rising focus on pediatric and high-risk cancer patients, is shaping the evolution of the market. For instance, in July 2024, Amneal Pharmaceuticals and Steriscience launched a novel ready-to-use injectable formulation of fosaprepitant, free from Polysorbate 80 and requiring no reconstitution. This single-dose vial, FOCINVEZ, supports adult and pediatric CINV prevention in highly and moderately emetogenic chemotherapy. The innovation enhances hospital and clinic workflow efficiency while improving patient safety and adherence. This launch is expected to significantly contribute to market growth during the forecast period by offering differentiated, patient-centric antiemetic solutions that align with ongoing demand for ready-to-administer therapies.

Chemotherapy Induced Nausea Vomiting Market Trends

Major market trends include rising clinical innovations, preference for combination therapies, and an emphasis on providing solutions for children among others.

Clinical Innovations to Bring Advanced Solutions in the Market

In October 2024, a phase 3 clinical study presented at the ASCO Quality Care Symposium revealed that olanzapine significantly outperformed prochlorperazine in managing severe refractory nausea after chemotherapy. This highlights a shift toward patient-centric treatment strategies beyond standard antiemetics. As clinical validation supports olanzapine’s efficacy, its wider adoption is expected to reshape supportive oncology care and drive growth in the CINV market during the forecast period.

Strategic Licensing to Fuel Combination Therapies and Impact Market Size Positively

In January 2023, Glenmark Pharmaceuticals launched Akynzeo IV, an injectable fixed-dose combination of fosnetupitant and palonosetron, under an exclusive licensing deal with Helsinn. This ready-to-dilute formulation simplifies administration in clinical settings, especially for highly emetogenic chemotherapy. Strategic partnerships like this are strengthening access to next-generation combination therapies, accelerating product adoption, and boosting the market’s growth.

Rising Pediatric Focus to Advance Targeted Chemotherapy Induced Nausea Vomiting Treatment

The growing inclusion of pediatric patients in chemotherapy regimens is increasing demand for age-specific antiemetic treatments. Formulations approved for use in young children are gaining traction as healthcare providers prioritize early intervention. This demographic shift is prompting pharmaceutical companies to invest in research and regulatory approvals for pediatric-friendly CINV therapies, opening new avenues for market expansion in the coming years.

Increased Hospital Reliance on Ready-to-use Injectables Supporting Chemotherapy Induced Nausea Vomiting Market Growth

With healthcare systems seeking efficiency and safety in drug administration, the demand for ready-to-use injectables is rising. These formulations reduce preparation time, minimize contamination risks, and improve workflow in oncology settings. As more antiemetic drugs are developed in pre-filled or single-dose formats, hospitals and cancer centres are expected to prefer them over traditional injectable therapies, thereby supporting growth in the market.

Chemotherapy Induced Nausea Vomiting Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

• Acute Emesis
• Delayed Emesis
• Anticipatory Emesis
• Refractory Emesis

Market Breakup by Therapy

• Nk-1 receptor antagonist
• Serotonin receptor antagonist
• Others

Market Breakup by Population Type

• Children
• Adults

Market Breakup by Drug Type

• Branded
• Generic

Market Breakup by Route of Administration

• Oral
• Parenteral
• Market Breakup by End User
• Hospitals
• Specialty Clinics
• Homecare Settings
• Others
• Market Breakup by Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Market Breakup by Region
• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Chemotherapy Induced Nausea Vomiting Market Share

Serotonin Receptor Antagonists to Lead the Market Share by Therapy

Serotonin receptor antagonists are expected to hold a substantial share due to their widespread use and proven efficacy. NK-1 receptor antagonists follow, offering enhanced control in combination therapies. The others category, including corticosteroids and novel agents, holds a smaller share but contributes to comprehensive treatment approaches, especially in patients with refractory symptoms or complex chemotherapy regimens.

Chemotherapy Induced Nausea Vomiting Market Analysis by Region

The United States is likely to hold the largest market share, driven by high chemotherapy adoption rates and access to advanced antiemetic therapies. Japan follows closely due to its ageing population and strong oncology care infrastructure. European countries Germany, France, Italy, Spain, and the UK, exhibit moderate growth with standardized treatment guidelines. India shows emerging potential, though limited access and affordability constraints currently restrict its overall market contribution.

Leading Players in the Chemotherapy Induced Nausea Vomiting Market

The key features of the market report comprise epidemiology, clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Dr. Reddy’s Laboratories Ltd

Founded in 1984 and headquartered in Hyderabad, India, Dr. Reddy’s Laboratories is a global pharmaceutical company with a strong presence in generics, active pharmaceutical ingredients, and biosimilars. In the chemotherapy-induced nausea and vomiting (CINV) market, it offers antiemetic formulations like Ondansetron and Palonosetron, supporting cancer care through affordable, high-quality medicines distributed across regulated and emerging markets.

CTX Lifesciences

Established in 2004 and headquartered in Surat, India, CTX Lifesciences is known for manufacturing APIs and intermediates, particularly for oncology and antiemetic segments. In the CINV market, the company provides active pharmaceutical ingredients like Ondansetron and Granisetron to global formulation companies, supporting cost-effective antiemetic drug production across various international regulatory frameworks.

Pfizer Inc

Headquartered in New York, USA, and founded in 1849, Pfizer is one of the world's largest biopharmaceutical companies. In the chemotherapy-induced nausea and vomiting (CINV) segment, Pfizer markets leading antiemetic products like Emend (Aprepitant), an NK1 receptor antagonist. Its innovative oncology support therapies are widely used in hospitals and oncology clinics globally.

Glenmark Pharmaceuticals Inc

Founded in 1977 and headquartered in Mumbai, India, Glenmark Pharmaceuticals operates internationally with a strong generics and specialty drug portfolio. In the chemotherapy induced nausea vomiting market, it offers generic formulations such as Ondansetron and Palonosetron. Glenmark supports global cancer treatment protocols by delivering accessible and effective antiemetic drugs to healthcare systems across developed and developing regions.

Other key players in the market include Gmt Pharma, Mountainside Medical, Cipla Limited, GlaxoSmithKline plc, Merck and Co. Inc., and Novartis AG.

Key Questions Answered in the Chemotherapy Induced Nausea Vomiting Market

• What was the chemotherapy induced nausea vomiting market value in 2024?
• What is the chemotherapy induced nausea vomiting market forecast outlook for 2025-2034?
• What are the major factors aiding the chemotherapy induced nausea vomiting market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major chemotherapy induced nausea vomiting market trends?
• Which typewill lead the market segment?
• Which therapy will lead the market segment?
• Which population type will lead the market segment?
• Which drug type will lead the market segment?
• Which route of administration will lead the market segment?
• Which end user will lead the market segment?
• Which distribution channel will lead the market segment?
• Who are the key players involved in the chemotherapy induced nausea vomiting market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.